Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director · Pres. & Chief Exec. Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,064 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 8,165 · Balance 29,644 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. Row 2 · 2026-10-05 · Sale · Disposed 8,580 · Balance 21,064 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold Descendants 2020 Trust | 8,038 |
Reported balance
After 2026-10-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-05 · Sale · Disposed 3,198 · Balance 8,038 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. |
| Common StockSEC Table I · non-derivative | IndirectBy Derek Maetzold 2020 Irrevocable Trust | 6,832 |
Reported balance
After 2026-10-05 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-05 · Sale · Disposed 2,718 · Balance 6,832 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2028-05-09 | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-10-05 · Exercise / conversion · Disposed 8,165 · Balance 0 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F13: The shares subject to the option are fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,256 F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 11,256 F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 11,256 F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 11,256 F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 6 | 11,963 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 11,963 F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 7 | 27,862 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 27,862 F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 8 | 40,935 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 40,935 F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectDJM Grantor Retained Annuity Trust No. 9 | 23,216 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 23,216 F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.
F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.
F13: The shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2021 Filed Jan 29, 2021 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,223 | $69.46 | $154,407.36 |
DisclosureSEC source: 0001447362-21-000020 · wf-form4_161195509756113.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 839,135 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $69.290 to $69.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 9,102 | $68.89 | $627,018.58 |
DisclosureSEC source: 0001447362-21-000020 · wf-form4_161195509756113.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 841,358 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $68.280 to $69.260, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,950 | $67.97 | $132,533.70 |
DisclosureSEC source: 0001447362-21-000020 · wf-form4_161195509756113.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,460 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $67.180 to $68.140, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,100 | $66.25 | $72,875.00 |
DisclosureSEC source: 0001447362-21-000020 · wf-form4_161195509756113.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,410 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $66.080 to $66.825, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,988 | $67.68 | $134,543.86 |
DisclosureSEC source: 0001447362-21-000020 · wf-form4_161195509756113.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 853,510 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $67.540 to $68.140, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,593 | $67.03 | $240,831.60 |
DisclosureSEC source: 0001447362-21-000020 · wf-form4_161195509756113.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,498 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $66.530 to $67.330, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,422 | $66.18 | $226,471.38 |
DisclosureSEC source: 0001447362-21-000020 · wf-form4_161195509756113.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 859,091 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $65.530 to $66.520, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,374 | $64.79 | $348,186.83 |
DisclosureSEC source: 0001447362-21-000020 · wf-form4_161195509756113.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 862,513 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.460 to $65.420, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 500 | $77.77 | $38,885.00 |
DisclosureSEC source: 0001447362-21-000016 · wf-form4_161109037611294.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,887 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $77.33 to $77.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,891 | $75.92 | $371,324.72 |
DisclosureSEC source: 0001447362-21-000016 · wf-form4_161109037611294.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 868,387 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $75.63 to $76.53, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,647 | $75.10 | $348,989.70 |
DisclosureSEC source: 0001447362-21-000016 · wf-form4_161109037611294.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 873,278 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $74.60 to $75.57, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,339 | $73.93 | $320,782.27 |
DisclosureSEC source: 0001447362-21-000016 · wf-form4_161109037611294.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,925 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $73.59 to $74.58, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,858 | $76.55 | $142,229.90 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 13 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,264 F6 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F14 · price: This transaction was executed in multiple trades at prices ranging from $76.33 to $76.93, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,142 | $75.80 | $238,163.60 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,122 F6 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F13 · price: This transaction was executed in multiple trades at prices ranging from $75.30 to $76.28, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,618 | $76.52 | $353,369.36 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,264 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F12 · price: This transaction was executed in multiple trades at prices ranging from $76.25 to $77.09, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,759 | $75.74 | $360,446.66 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 10 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891,882 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F11 · price: This transaction was executed in multiple trades at prices ranging from $75.25 to $76.24, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 611 | $74.56 | $45,556.16 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 896,641 F6 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $74.44 to $74.81, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,589 | $73.84 | $191,171.76 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 897,252 F6 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $73.40 to $74.38, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,530 | $72.86 | $111,475.80 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899,841 F6 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $72.36 to $73.06, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 270 | $71.66 | $19,348.20 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,371 F6 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $71.35 to $72.32, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 100 | $76.78 | $7,678.00 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,641 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 603 | $74.52 | $44,935.56 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,741 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $74.41 to $74.61, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,118 | $73.96 | $378,527.28 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902,344 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $73.40 to $74.37, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,156 | $72.94 | $230,198.64 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907,462 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $72.40 to $73.36, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 400 | $71.36 | $28,544.00 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 910,618 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.17 to $71.52, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 100 | $69.72 | $6,972.00 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,252 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,645 | $69.02 | $389,634.84 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 10 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,352 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $68.680 to $69.600, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 9,255 | $68.33 | $632,431.17 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,997 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $67.660 to $68.650, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 300 | $73.69 | $22,107.90 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,272,252 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $73.670 to $73.710, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 300 | $72.06 | $21,616.50 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,272,552 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $71.920 to $72.200, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 500 | $70.31 | $35,153.00 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,272,852 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $70.110 to $71.090, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 100 | $69.11 | $6,911.00 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273,352 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,000 | $67.72 | $67,720.00 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273,452 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $67.500 to $68.250, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,950 | $66.80 | $263,860.00 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,274,452 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $66.500 to $67.485, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,229 | $66.07 | $279,401.57 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,278,402 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $65.470 to $66.430, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,621 | $64.91 | $299,935.25 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282,631 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.420 to $65.400, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 21, 2020 Filed Jan 11, 2021 21:55 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GiftCommon Stock | 179,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000002 · wf-form5_161040210937227.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,149 F2 · shares: On December 21, 2020, the reporting person transferred 179,300 shares of Castle Biosciences, Inc. common stock to The Maetzold Descendants 2020 Trust of which the reporting person is trustee and his children are beneficiaries. Read SEC document |
| December 21, 2020 Filed Jan 11, 2021 21:55 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GiftCommon Stock | 166,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000002 · wf-form5_161040210937227.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,087,449 F1 · shares: On December 21, 2020, the reporting person transferred 166,700 shares of Castle Biosciences, Inc. common stock to the Derek Maetzold 2020 Irrevocable Trust of which the reporting person's spouse is the trustee and the reporting person's spouse and their children are beneficiaries. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 100 | $65.02 | $6,502.00 |
DisclosureSEC source: 0001447362-20-000299 · wf-form4_160858476630804.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,287,252 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 500 | $64.21 | $32,105.00 |
DisclosureSEC source: 0001447362-20-000299 · wf-form4_160858476630804.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,287,352 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $63.86 to $64.36, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,521 | $63.01 | $95,838.21 |
DisclosureSEC source: 0001447362-20-000299 · wf-form4_160858476630804.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,287,852 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $62.74 to $63.42, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,129 | $62.20 | $256,823.80 |
DisclosureSEC source: 0001447362-20-000299 · wf-form4_160858476630804.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289,373 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $61.66 to $62.62, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 81 | $69.27 | $5,610.79 |
DisclosureSEC source: 0001447362-20-000297 · wf-form4_160832530700817.xml · nonDerivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,293,502 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F12 · price: This transaction was executed in multiple trades at prices ranging from $68.930 to $69.440, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 473 | $68.18 | $32,249.14 |
DisclosureSEC source: 0001447362-20-000297 · wf-form4_160832530700817.xml · nonDerivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,293,583 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F11 · price: This transaction was executed in multiple trades at prices ranging from $67.710 to $68.700, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,024 | $67.00 | $68,604.93 |
DisclosureSEC source: 0001447362-20-000297 · wf-form4_160832530700817.xml · nonDerivative · entry 10 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,294,056 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $66.475 to $67.375, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,360 | $64.95 | $88,326.56 |
DisclosureSEC source: 0001447362-20-000297 · wf-form4_160832530700817.xml · nonDerivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,295,080 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $64.610 to $65.600, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,012 | $63.91 | $128,586.92 |
DisclosureSEC source: 0001447362-20-000297 · wf-form4_160832530700817.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,296,440 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $63.540 to $64.500, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,300 | $63.10 | $82,032.60 |
DisclosureSEC source: 0001447362-20-000297 · wf-form4_160832530700817.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,298,452 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $62.510 to $63.470, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 100 | $68.65 | $6,865.00 |
DisclosureSEC source: 0001447362-20-000297 · wf-form4_160832530700817.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,299,752 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 560 | $67.69 | $37,908.64 |
DisclosureSEC source: 0001447362-20-000297 · wf-form4_160832530700817.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,299,852 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $67.625 to $67.815, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.